Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts

  • Dušan Milanović1, 4Email author,
  • Friederike Braun2,
  • Wolfgang Weber2,
  • Anca Ligia Grosu1,
  • Martin Behe3 and
  • Gabriele Niedermann1
BMC Cancer201212:242

DOI: 10.1186/1471-2407-12-242

Received: 17 January 2012

Accepted: 5 June 2012

Published: 13 June 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
17 Jan 2012 Submitted Original manuscript
9 Feb 2012 Reviewed Reviewer Report - Dan Duda
27 Mar 2012 Reviewed Reviewer Report - Bernd Joachim Krause
7 May 2012 Author responded Author comments - Dusan Milanovic
Resubmission - Version 2
7 May 2012 Submitted Manuscript version 2
7 May 2012 Author responded Author comments - Dusan Milanovic
Resubmission - Version 3
7 May 2012 Submitted Manuscript version 3
21 May 2012 Reviewed Reviewer Report - Dan Duda
24 May 2012 Reviewed Reviewer Report - Bernd Joachim Krause
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
5 Jun 2012 Editorially accepted
13 Jun 2012 Article published 10.1186/1471-2407-12-242

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Department of Radiation Oncology, University Hospital Freiburg
(2)
Department of Nuclear Medicine, University Hospital Freiburg
(3)
Paul Scherer Institut, Center for Radiopharmaceutical Sciences
(4)
Department of Radiation Oncology, University Hospital Freiburg

Advertisement